-
Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2024-04-19 Pei-Chien Tsai, Chung-Feng Huang, Ming-Lun Yeh, Meng-Hsuan Hsieh, Hsing-Tao Kuo, Chao-Hung Hung, Kuo-Chih Tseng, Hsueh-Chou Lai, Cheng-Yuan Peng, Jing-Houng Wang, Jyh-Jou Chen, Pei-Lun Lee, Rong-Nan Chien, Chi-Chieh Yang, Gin-Ho Lo, Jia-Horng Kao, Chun-Jen Liu, Chen-Hua Liu, Sheng-Lei Yan, Chun-Yen Lin, Wei-Wen Su, Cheng-Hsin Chu, Chih-Jen Chen, Shui-Yi Tung, Chi-Ming Tai, Chih-Wen Lin, Ching-Chu Lo
Chronic hepatitis C (CHC) patients who fail antiviral therapy have a high risk of developing hepatocellular carcinoma (HCC). We investigated the effects of metformin and statins, commonly used to treat diabetes mellitus (DM) and hyperlipidemia (HLP), on HCC risk in CHC patients who failed antiviral therapy.
-
Global prevalence of MAFLD-related hepatocellular carcinoma: A systematic review and meta-analysis. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2024-04-16 Harry Crane, Guy D Eslick, Cameron Gofton, Anjiya Shaikh, George Cholankeril, Mark Cheah, Jian-Hong Zhong, Gianluca Svegliati-Baroni, Alessandro Vitale, Beom Kyung Kim, Sang Hoon Ahn, Mi Na Kim, Simone Strasser, Jacob George
The global proportion of hepatocellular carcinoma (HCC) attributable to metabolic dysfunction-associated fatty liver disease (MAFLD) is unclear. The MAFLD diagnostic criteria allows objective diagnosis in the presence of steatosis plus defined markers of metabolic dysfunction, irrespective of concurrent liver disease. We aimed to determine the total global prevalence of MAFLD in HCC cohorts (total-MAFLD)
-
Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against non-alcoholic fatty liver disease. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2024-04-16 Yiyuan Zheng, Lina Zhao, Zhekun Xiong, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Yugang Fu, Simin Gu, Chong Chen, Jiacheng Li, Yingying Zhu, Jing Liu, Fengbin Liu, Yong Li
Non-alcoholic fatty liver disease (NAFLD) has become an increasingly important health challenge, with a substantial rise linked to changing lifestyles and global obesity. Ursolic acid, a natural pentacyclic triterpenoid, has been explored for its potential therapeutic effects. Given its multifunctional bioactive properties, this research further revealed the pharmacological mechanisms of ursolic acid
-
Ischemia-free liver transplantation improves the prognosis of recipients using Functioned Marginal Liver grafts. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2024-04-11 Shuai Wang, Xiaohong Lin, Yunhua Tang, Yichen Liang, Min Zhang, Zhonghao Xie, Yiwen Guo, Yuqi Dong, Qiang Zhao, Zhiyong Guo, Dongping Wang, Xiaoshun He, Weiqiang Ju, Maogen Chen
The shortage of donor livers hinders the development of liver transplantations. This study aimed to clarify the poor outcomes of functioned marginal liver grafts (FMLs) and provide evidence for the improvement of ischemia-free liver transplantation (IFLT) on transplantation with FMLs.
-
Conventional and machine-learning based risk score for patients with early-stage hepatocellular carcinoma. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2024-04-11 Chun-Ting Ho, Elise Chia-Hui Tan, Pei-Chang Lee, Chi-Jen Chu, Yi-Hsiang Huang, Teh-Ia Huo, Yu-Hui Su, Ming-Chih Hou, Jaw-Ching Wu, Chien-Wei Su
The performance of machine-learning (ML) in predicting the outcomes of patients with hepatocellular carcinoma (HCC) remains uncertain. We aimed to develop risk scores using conventional methods and ML to categorize early-stage HCC patients into distinct prognostic groups.
-
Dynamic Assessment of Modified Quick Sequential Organ Failure Assessment in Acutely Deteriorated Patients with Chronic Liver Disease. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2024-04-11 Do Seon Song, Hee Yeon Kim, Young Kul Jung, Tae Hyung Kim, Hyung Joon Yim, Eileen L Yoon, Ki Tae Suk, Jeong-Ju Yoo, Sang Gyune Kim, Moon Young Kim, Young Chang, Soung Won Jeong, Jae Young Jang, Sung-Eun Kim, Jung-Hee Kim, Jung Gil Park, Won Kim, Jin Mo Yang, Dong Joon Kim, , Ashok Kumar Choudhury, Vinod Arora, Shiv Kumar Sarin
Quick sequential organ failure assessment (qSOFA) has been suggested to identify those who have poor outcomes in patients with suspected infection. We aimed to evaluate the ability of the modified qSOFA (m-qSOFA) to identify high-risk patients in acutely deteriorated patients with chronic liver disease (CLD), especially acute-on-chronic liver failure (ACLF).
-
Phase 1 Trial of the Safety, Pharmacokinetics, and Antiviral Activity of EDP-514 in Untreated Viremic Chronic Hepatitis B Patients. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2024-03-26 Man-Fung Yuen, Wan-Long Chuang, Cheng-Yuan Peng, Wen-Juei Jeng, Wei-Wen Su, Ting-Tsung Chang, Chi-Yi Chen, Yao-Chun Hsu, Guy De La Rosa, Alaa Ahmad, Ed Luo, Annie L Conery
Oral EDP-514 is a potent core protein inhibitor of hepatitis B virus (HBV) replication, which produced a >4-log viral load reduction in HBV-infected chimeric mice with human liver cells. This study evaluated the safety, pharmacokinetics (PK), and antiviral activity of three doses of EDP-514 in treatment naïve viremic patients with HBeAg-positive or -negative chronic HBV infection.
-
Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2024-03-15 Jiwon Hong, Jung Woo Eun, Geum Ok Baek, Jae Youn Cheong, Seryoung Park, Soon Sun Kim, Hyo Jung Cho, Su Bin Lim
Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide. Despite identification of several biomarkers for HCC diagnosis, challenges such as low sensitivity and intratumoral heterogeneity have impeded early detection, highlighting the need for etiology-specific blood biomarkers.
-
Liver Sinusoidal Endothelial Cell: An Important Yet Often Overlooked Player in the Liver Fibrosis. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2024-02-28 Jiaorong Qu, Le Wang, Yufei Li, Xiaojiaoyang Li
Liver sinusoidal endothelial cells (LSECs) are liver-specific endothelial cells with the highest permeability than other mammalian endothelial cells, characterized by the presence of fenestrae on their surface, the absence of diaphragms and lack of basement membrane. Located at the interface between blood and other liver cell types, LSECs mediate the exchange of substances between the blood and the
-
Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2024-01-26 Michael H Le, David M Le, Thomas C Baez, Hansen Dang, Vy H Nguyen, KeeSeok Lee, Christopher D Stave, Takanori Ito, Yuankai Wu, Yee Hui Yeo, Fanpu Ji, Ramsey Cheung, Mindie H Nguyen
Nonalcoholic fatty liver disease (NAFLD) is associated with a multitude of adverse outcomes. We aimed to estimate the pooled incidence of NAFLD-related adverse events.
-
Identification of signature gene set as highly accurate determination of MASLD progression. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2024-01-26 Sumin Oh, Yang-Hyun Baek, Sungju Jung, Sumin Yoon, Byeonggeun Kang, Su-Hyang Han, Gaeul Park, Je Yeong Ko, Sang-Young Han, Jin-Sook Jeong, Jin-Han Cho, Young-Hoon Roh, Sung-Wook Lee, Gi-Bok Choi, Yong Sun Lee, Won Kim, Rho Hyun Seong, Jong Hoon Park, Yeon-Su Lee, Kyung Hyun Yoo
Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by fat accumulation in the liver. MASLD encompasses both steatosis and MASH. Since MASH can lead to cirrhosis and liver cancer, steatosis and MASH must be distinguished during patient treatment. Here, we investigate the genomes, epigenomes, and transcriptomes of MASLD patients to identify signature gene set for more accurate
-
Prognosis of biopsy-confirmed MASLD: a sub-analysis of the CLIONE study. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2024-01-24 Michihiro Iwaki, Hideki Fujii, Hideki Hayashi, Hidenori Toyoda, Satoshi Oeda, Hideyuki Hyogo, Miwa Kawanaka, Asahiro Morishita, Kensuke Munekage, Kazuhito Kawata, Tsubasa Tsutsumi, Koji Sawada, Tatsuji Maeshiro, Hiroshi Tobita, Yuichi Yoshida, Masafumi Naito, Asuka Araki, Shingo Arakaki, Takumi Kawaguchi, Hidenao Noritake, Masafumi Ono, Tsutomu Masaki, Satoshi Yasuda, Eiichi Tomita, Masato Yoneda,
Metabolic dysfunction-associated steatotic liver disease (MASLD) was recently proposed as an alternative disease concept to nonalcoholic fatty liver disease (NAFLD). We aimed to investigate the prognosis in patients with biopsy-confirmed MASLD using data from a multicenter study.
-
Comprehensive Approach to Controlling Chronic Hepatitis B in China. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2024-01-05 Shan Shan, Xinyan Zhao, Jidong Jia
Hepatitis B virus (HBV) infection was highly endemic in China, where the prevalence of HBsAg was 9.7% in 1992. Comprehensive strategies, including universal infant hepatitis B vaccination with emphasis on timely birth-dose and 3-dose coverage, dramatically reduced the mother-to-infant transmission and early childhood acquisition of HBV, resulting in estimated HBsAg prevalence rates of 5.6% and 0.1%
-
Protein-Centric Omics Analysis Reveals Circulating Complements Linked to Non-Viral Liver Diseases as Potential Therapeutic Targets. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-12-07 Yingzhou Shi, Hang Dong, Shiwei Sun, Xiaoqin Wu, Jiansong Fang, Jianbo Zhao, Junming Han, Zhongyue Li, Huixiao Wu, Luna Liu, Wanhong Wu, Yang Tian, Guandou Yuan, Xiude Fan, Chao Xu
To evaluate the causal correlation between complement components and non-viral liver diseases and their potential use as druggable targets.
-
Correspondence on a Letter regarding "Waiting for the changes after the adoption of steatotic liver disease (MASLD)". Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-11-28 Eileen L Yoon,Dae Won Jun
-
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-11-21 Ming-Ying Lu, Chung-Feng Huang, Chao-Hung Hung, Chi-Ming Tai, Lein-Ray Mo, Hsing-Tao Kuo, Kuo-Chih Tseng, Ching-Chu Lo, Ming-Jong Bair, Szu-Jen Wang, Jee-Fu Huang, Ming-Lun Yeh, Chun-Ting Chen, Ming-Chang Tsai, Chien-Wei Huang, Pei-Lun Lee, Tzeng-Hue Yang, Yi-Hsiang Huang, Lee-Won Chong, Chien-Lin Chen, Chi-Chieh Yang, Sheng-Shun Yang, Pin-Nan Cheng, Tsai-Yuan Hsieh, Jui-Ting Hu, Wen-Chih Wu, Chien-Yu
Despite the high efficacy of direct-acting antivirals (DAAs), approximately 1-3% of hepatitis C virus (HCV) patients fail to achieve a sustained virological response. We conducted a nationwide study to investigate risk factors associated with DAA treatment failure. Machine-learning algorithms have been applied to discriminate subjects who may fail to respond to DAA therapy.
-
Cardiovascular Risk in Chronic Hepatitis B Patients Treated with Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-11-20 Hyeyeon Hong,Won-Mook Choi,Danbi Lee,Ju Hyun Shim,Kang Mo Kim,Young-Suk Lim,Han Chu Lee,Jonggi Choi
Background/Aims Tenofovir disoproxil fumarate (TDF) is known to have a lipid-lowering effect. This is in contrast to tenofovir alafenamide (TAF), which has a lipid-neutral effect. Therefore, concerns have been raised as to whether these differences affect long-term cardiovascular risk. Here, we aimed to evaluate the long-term risk of cardiovascular events in chronic hepatitis B (CHB) patients treated
-
Disseminating Steatotic Liver Disease Patient Education: The Emerging Role of Large Language Models. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-11-14 Yee Hui Yeo,Ju Dong Yang
-
It is time to consider a new paradigm shift in Steatotic Liver Disease in Asia. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-11-14 Kuo Chao Yew,Sunny H Wong,Vincent Wai-Sun Wong,Hazel H Oon
-
Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-11-13 Soomin Ahn,Sook-Hyang Jeong,Eun Ju Cho,Kyoungbun Lee,Gilhyang Kim,Haeryoung Kim
Background The histological criteria in the 1999 and 2008 scoring systems proposed by the International Autoimmune Hepatitis Group (IAIHG) have their inherent limitations in diagnosing autoimmune hepatitis (AIH). In this study, we evaluated the histology components of four scoring systems [1) revised original scoring system ("1999 IAIHG"), 2) simplified scoring system ("2008 IAIHG"), 3) modified histologic
-
Assessing State-of-the-Art Online Large Language Models for Patient Education Regarding Steatotic Liver Disease. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-11-10 Yiwen Zhang,Liwei Wu,Zepeng Mu,Linlin Ren,,Tien Yin Wong,Hongwei Ji
-
Erratum to 'Correspondence on Letter regarding "Evidencebased hyponatremia management in liver disease"' [Clin Mol Hepatol 2023;29:1048-1049]. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-11-07 Seon Ha Baek,Ji Young Ryu,Sejoong Kim
-
Comment on "ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma." Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-10-13 Hinpetch Daungsupawong,Viroj Wiwanitkit
-
Recent Updates on Pharmacologic Therapy in Nonalcoholic Fatty Liver Disease. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-10-13 Young Chang,Soung Won Jeong,Jae Young Jang
-
Letter regarding "Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma". Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-10-11 Chi Hsiao,Yung-Po Liaw
-
TASL-TSOC Taiwan Position Statement for the Management of Metabolic Dysfunction-Associated Fatty Liver Disease and Cardiovascular Diseases. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-10-04 Pin-Nan Cheng, Wen-Jone Chen, Charles Jia-Yin Hou, Chih-Lin Lin, Ming-Ling Chang, Chia-Chi Wang, Wei-Ting Chang, Chao-Yung Wang, Chun-Yen Lin, Chung-Lieh Hung, Cheng-Yuan Peng, Ming-Lung Yu, Ting-Hsing Chao, Jee-Fu Huang, Yi-Hsiang Huang, Chi-Yi Chen, Chern-En Chiang, Han-Chieh Lin, Yi-Heng Li, Tsung-Hsien Lin, Chia-Horng Kao, Tzung-Dau Wang, Ping-Yen Liu, Yen-Wen Wu, Chun-Jen Liu
Metabolic dysfunction associated fatty liver disease (MAFLD) is an increasingly important and common liver disease worldwide. The diagnosis of MAFLD is based on the presence of steatosis on image/histology/serum markers accompanied with presence of at least one of the three metabolic features that include overweight/obesity, type II diabetes mellitus, and metabolic risk factors. MAFLD is not only a
-
Adding to the confusion in more than just the name. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-09-18 Jacob George
-
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-09-18 Ming-Lun Yeh,Ming-Lung Yu
-
Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: a longitudinal real-world study. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-09-11 Vy H Nguyen, Isaac Le, Audrey Ha, Richard Hieu Le, Nicholas Ajit Rouillard, Ashley Fong, Surya Gudapati, Jung Eun Park, Mayumi Maeda, Scott Barnett, Ramsey Cheung, Mindie H Nguyen
Understanding of nonalcoholic fatty liver disease (NAFLD) continues to expand, but the relationship between race and ethnicity and NAFLD outside the use of cross-sectional data is lacking. Using longitudinal data, we investigated the role of race and ethnicity in adverse outcomes in NAFLD patients.
-
Waiting for the changes after the adoption of steatotic liver disease. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-09-06 Eileen L Yoon,Dae Won Jun
Steatotic liver disease was suggested as an overarching term encompassing various etiologies of hepatic steatosis. Experts from multinational liver societies went through the Delphi process, including four rounds of surveys, and consented to adopt a new nomenclature and definition instead of the conventional nonalcoholic fatty liver disease (NAFLD). This was to improve the understanding of the patients
-
Novel paradigm in the treatment of hepatocellular carcinoma: Anticipating breakthroughs with particle therapy. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-08-31 Sang Min Yoon
-
Correspondence on Letter regarding "Risk factors in nonalcoholic fatty liver disease". Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-08-29 Eileen L Yoon,Dae Won Jun
-
Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-08-29 Sung Uk Lee, Tae Hyun Kim
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death, and external beam radiation therapy has emerged as a promising approach for managing HCC. Proton beam therapy (PBT) offers dosimetric advantages over X-ray therapy, with superior physical properties known as the Bragg peak. PBT holds promise for reducing hepatotoxicity and allowing safe dose-escalation to the tumor. It has been
-
Prognostic role of computed tomography analysis using deep learning algorithm in patients with chronic hepatitis B viral infection. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-08-29 Jeongin Yoo, Heejin Cho, Dong Ho Lee, Eun Ju Cho, Ijin Joo, Sun Kyung Jeon
The prediction of clinical outcomes in patients with chronic hepatitis B (CHB) is paramount for effective management. This study aimed to evaluate the prognostic value of computed tomography (CT) analysis using deep learning algorithms in patients with CHB.
-
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-08-25 Gi-Ae Kim,Joon Ho Moon,Won Kim
The existing term non-alcoholic fatty liver disease (NAFLD) has raised substantial concerns due to its inherent disadvantages of using exclusionary diagnostic criteria and the stigmatizing word 'fatty.' Three pan-national liver associations set out to explore a new nomenclature to replace both NAFLD and its suggested alternative, metabolic (dysfunction)-associated fatty liver disease (MAFLD). They
-
Letter regarding "Risk factors in nonalcoholic fatty liver disease". Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-08-22 Abhijit Pratap,Umesh More,Pradnya Phalak,Anita Deshmukh
-
Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean? Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-08-16 Eugene Han,Yong-Ho Lee
-
Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma? Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-08-14 Hyo-Cheol Kim
-
Correspondence on Letter regarding "Evidence-based hyponatremia management in liver disease". Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-08-14 Ji Young Ryu,Seon Ha Baek,Sejoong Kim
-
Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-08-14 Hwa Kyung Byun, Changhwan Kim, Jinsil Seong
Hepatocellular carcinoma (HCC) is a highly lethal cancer with limited treatment options and poor prognosis. Carbon ion radiotherapy (CIRT) has emerged as a promising treatment modality for HCC due to its unique physical and biological properties. CIRT uses carbon ions to target and destroy cancer cells with a high precision and efficacy. The Bragg Peak phenomenon allows precise dose delivery to the
-
The role of the hepatic autonomic nervous system. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-07-25 Qiankun Luo,Pan Liu,Yifei Dong,Tao Qin
-
Recent advances in the management of hepatocellular carcinoma. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-07-21 Kamya Sankar,Jun Gong,Arsen Osipov,Steven A Miles,Kambiz Kosari,Nicholas N Nissen,Andrew E Hendifar,Ekaterina K Koltsova,Ju Dong Yang
Liver cancer remains a challenge of global health, being the 4th leading cause of cancer death worldwide. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and is usually precipitated by chronic viral infections (hepatitis B and C), non-alcoholic steatohepatitis, heavy alcohol use, and other factors which may lead to chronic inflammation and cirrhosis of the liver. There
-
Letter regarding "Evidence-based hyponatremia management in liver disease". Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-07-05 Daphne J Theodorou,Stavroula J Theodorou,Ioannis V Mitselos
-
Lsoco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma : a network meta-analysis. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-07-05 Ha Il Kim, Jihyun An, Seungbong Han, Ju Hyun Shim
There is no clear consensus on the relative ranking of interventional and radiation techniques with indications similar to those of radiofrequency ablation (RFA) for the treatment of early hepatocellular carcinoma (HCC). We used a network meta-analysis to compare the efficacy of non-surgical treatments for early HCC.
-
Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-07-05 Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe
Aim To investigate whether non-alcoholic fatty liver disease (NAFLD) in individuals without generalized obesity is associated with visceral fat obesity (VFO), sarcopenia, and/or myosteatosis. Methods This cross-sectional analysis included 14,400 individuals (7,470 men) who underwent abdominal computed tomography (CT) scans during routine health examinations. The total abdominal muscle area (TAMA) and
-
Evidence-based hyponatremia management in liver disease. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-06-05 Ji Young Ryu,Seon Ha Baek,Sejoong Kim
Hyponatremia is primarily a water balance disorder associated with high morbidity and mortality. The pathophysiological mechanisms behind hyponatremia are multifactorial, and diagnosing and treating this disorder remains challenging. In this review, the classification, pathogenesis, and step-by-step management approaches for hyponatremia in patients with liver disease are described based on recent
-
Correspondence on Letter 1 regarding "Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma". Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-05-31 Yee Hui Yeo,Jamil S Samaan,Wee Han Ng
-
HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations? Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-05-31 Soon Kyu Lee,Jung Hyun Kwon
-
Correspondence on Letter 2 regarding "Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma". Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-05-31 Yee Hui Yeo,Jamil S Samaan,Wee Han Ng
-
The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-05-30 Xianhua Mao,Lung Yi Mak,Wai-Kay Seto
-
Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-05-30 Moon Haeng Hur,Yuri Cho,Do Young Kim,Jae Seung Lee,Gyoung Min Kim,Hyo-Cheol Kim,Dong Hyun Sinn,Dongho Hyun,Han Ah Lee,Yeon Seok Seo,In Joon Lee,Joong-Won Park,Yoon Jun Kim
BACKGROUND/AIMS Transarterial radioembolization (TARE) has shown promising results in treating advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). However, whether TARE can provide superior or comparable outcomes to tyrosine kinase inhibitor (TKI) in patients with HCC and PVTT remains unclear. We compared the outcomes of TARE and TKI therapy in treatment-naïve patients
-
The Evolving Role of Lenvatinib at the New Era of First-Line HCC Treatment. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-05-25 Landon L Chan, Stephen L Chan
Emergence of multi-targeted kinase inhibitors (MTIs) and immune checkpoint inhibitors (ICI) have changed the landscape of management in hepatocellular carcinoma (HCC). Combination therapy involving ICI has superseded sorafenib as the first-line treatment option for advanced HCC due to their superior response rates and survival benefits based on recently published phase III trials. However, the role
-
Letter 2 regarding "Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma". Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-05-24 Amnuay Kleebayoon,Viroj Wiwanitkit
-
Correspondence on Letter regarding "Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?" Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-05-19 Joo Hyun Oh,Dong Hyun Sinn
-
Letter 1 regarding "Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma". Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-05-19 Hassam Ali
-
Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-05-17 Jeayeon Park,Sung Won Chung,Yun Bin Lee,Hyunjae Shin,Moon Haeng Hur,Heejin Cho,Min Kyung Park,Jeonghwan Youk,Ji Yun Lee,Jeong-Ok Lee,Su Jong Yu,Yoon Jun Kim,Jung-Hwan Yoon,Tae Min Kim,Jeong-Hoon Lee
BACKGROUND/AIMS Chronic hepatitis B (CHB) is a risk factor for non-Hodgkin lymphoma (NHL). Our recent study suggested that antiviral treatment may reduce the incidence of NHL in CHB patients. This study compared the prognoses of hepatitis B virus (HBV)-associated diffuse large B-cell lymphoma (DLBCL) patients receiving antiviral treatment and HBV-unassociated DLBCL patients. METHODS This study comprised
-
Correspondence on Letter regarding "Non-alcoholic fatty liver disease: Definition and subtypes". Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-05-17 Seul Ki Han,Soon Koo Baik,Moon Young Kim
-
Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-05-15 Chang Hun Lee,Gwang Hyeon Choi,Hwa Young Choi,Sojung Han,Eun Sun Jang,Young Eun Chon,Young Chang,Kyung-Ah Kim,Do Young Kim,Hyung Joon Yim,Hye-Lin Kim,Sook-Hyang Jeong,In Hee Kim
BACKGROUND/AIMS To eliminate hepatitis B virus (HBV) and hepatitis C virus (HCV) according to the World Health Organization (WHO) criteria in 2021, this study investigated the national core indicators representing the current status of viral hepatitis B and C in South Korea. METHODS We analyzed the incidence, linkage-to-care, treatment, and mortality rates of HBV and HCV infection using the integrated
-
Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients. Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-05-10 Xiaoning Wu,Xiaoqian Xu,Jialing Zhou,Yameng Sun,Huiguo Ding,Wen Xie,Guofeng Chen,Anlin Ma,HongXin Piao,Bingqiong Wang,Shuyan Chen,Tongtong Meng,Xiaojuan Ou,Hwai-I Yang,Jidong Jia,Yuanyuan Kong,Hong You
BACKGROUND/AIMS Existing hepatocellular carcinoma (HCC) prediction models are derived mainly from pretreatment or early on-treatment parameters. We reassessed the dynamic changes in the performance of 17 HCC models in patients with chronic hepatitis B (CHB) during long-term antiviral therapy (AVT). METHODS Among 987 CHB patients administered long-term entecavir therapy, 660 patients had 8 years of
-
Letter regarding "Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?" Clin. Mol. Hepatol. (IF 8.9) Pub Date : 2023-05-08 Halil Haldun Emiroglu